# **CDER GUIDANCES**

### NEW/REVISED/WITHDRAWN

#### 1/1/2005 -4/30/2005

(Sorted by date)

| Title  | Subject                          | Level<br>at<br>Date of<br>Issue | Publication/<br>Withdrawal<br>Date | Status  |
|--|----------------------------------|---------------------------------|------------------------------------|---------|
| Labeling Over-the-Counter Human Drug<br>Products; Questions and Answers  | OTC Draft                        | Level 1                         | 1/13/2005                          | New     |
| Nonclinical Safety Evaluation of Drug<br>Combinations  | Pharmacology<br>Toxicology Draft | Level 1                         | 1/26/2005                          | New     |
| Abbreviated New Drug Applications: Impurities in Drug Substances; Chemistry, Manufacturing, and Controls Information | Chemistry Draft                  | Level 1                         | 1/31/2005                          | New     |
| S8 Immunotoxicity Studies for Human Pharmaceuticals  | ICH Safety Draft                 | Level 1                         | 2/8/2005                           | New     |
| Clinical Lactation Studies-Study Design, Data<br>Analysis, and Recommendations for Labeling                          | Clinical Medical Draft           | Level 1                         | 2/8/2005                           | New     |
| Q8 Pharmaceutical Development  | ICH Quality Draft                | Level 1                         | 2/9/2005                           | New     |
| Internal Radioactive Contamination-<br>Development of Decorporation Agents   | Clinical Medical Draft           | Level 1                         | 2/15/2005                          | New     |
| E2B(M) Questions and Answers   | ICH Efficacy                     | Level 2                         | 3/9/2005                           | Revised |
| Centralized IRB Review Proceedings in<br>Multicenter Clinical Trials   | Procedural Draft                 | Level 1                         | 3/28/2005                          | New     |
| Systemic Lupus Erythematosus-Developing Drugs for Treatment  | Clinical Medical Draft           | Level 1                         | 3/29/2005                          | New     |

# **CDER GUIDANCES**

### NEW/REVISED/WITHDRAWN

#### 1/1/2005 -4/30/2005

(Sorted by date)

| Clinical Trial Endpoints for the Approval of<br>Cancer Drugs and Biologics   | Clinical Medical Draft           | Level 1 | 4/4/2005  | New |
|--|----------------------------------|---------|-----------|-----|
| Exploratory IND Studies  | Pharmacology<br>Toxicology Draft | Level 1 | 4/14/2005 | New |
| User Fee Waivers for Fixed Dose Combination<br>Products and Co-Packaged Human<br>Immunodeficiency Virus Drugs for the<br>President's Emergency Plan for Acquired<br>Immunodeficiency Syndrome Relief | User Fee Draft                   | Level 1 | 4/18/2005 | New |